Chat with us, powered by LiveChat Colibri Resource Corp. | Agm Postponed Due To Ffcto And Tsxv Trading Suspension

News

Agm Postponed Due To Ffcto And Tsxv Trading Suspension

May 18, 2022

DIEPPE, N.B., May 18, 2022 -- Colibri Resource Corporation (“Colibri” or the “Company”) (CBI: TSX-V) Further to the Company’s news release disseminated on April 29, 2022, Colibri announces that, as a result of a Failure-to-File Cease Trade Order issued by the New Brunswick Financial and Consumer Services Commission on May 11, 2022 and a suspension in trading imposed by the TSX Venture Exchange on May 12, 2022, it has postponed its annual general meeting originally scheduled for June 23, 2022. A revised meeting date will be announced once the Company has moved closer towards a definitive completion and filing date for its audited financial statements for the period ending December 31, 2021 and its interim financial statements for the 3 month period ending March 31, 2022.

About Colibri Resource Corporation

Colibri is a Canadian-based mineral exploration company listed on the TSX-V (CBI) and is focused on acquiring and exploring prospective gold & silver properties in Mexico. The Company has six exploration projects of which five currently have exploration programs being executed in 2022. (1) The flagship Evelyn Gold Project is 100% owned and explored by Colibri, (2) the Pilar Gold & Silver Project (optioned to Tocvan Ventures Corp. - (CSE: TOC), (3) the El Mezquite Gold & Silver Project, (4) the Jackie Gold & Silver Project, and (5) the Diamante Gold & Silver Project. 3,4, and 5 are subject to earn-in agreements by Silver Spruce Resources Inc. - TSXV: SSE).

For more information about all Company projects please visit: www.colibriresource.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

Information in this press release that involves Colibri’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Colibri generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the timing and completion of necessary accounting and review procedures to complete the Annual Filings and other factors beyond our control. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Colibri’s management. The forward-looking statements in this press release are based upon information available to Colibri as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Colibri and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to negotiate and enter into a definitive agreement with Molecular You; failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Colibri’s public filings available on SEDAR at www.sedar.com. Accordingly, readers should exercise caution in relying upon forward-looking statements and Colibri undertakes no obligation to publicly revise them to reflect subsequent events or circumstances, except as required by applicable law.

For further information, please contact:

Ronald J. Goguen, President, CEO and Director

Tel: (506) 383-4274